310 712

Cited 55 times in

Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions.

DC Field Value Language
dc.contributor.authorKim, YH-
dc.contributor.authorPark, SW-
dc.contributor.authorLee, CW-
dc.contributor.authorHong, MK-
dc.contributor.authorGwon, HC-
dc.contributor.authorJang, Y-
dc.contributor.authorLee, MM-
dc.contributor.authorKoo, BK-
dc.contributor.authorOh, DJ-
dc.contributor.authorSeung, KB-
dc.contributor.authorTahk, SJ-
dc.contributor.authorYoon, J-
dc.contributor.authorPark, SJ-
dc.description.abstractOBJECTIVE: This study compared the efficacy of the sirolimus-eluting stent (SES), the paclitaxel-eluting stent (PES), and the bare metal stent (BMS) for long coronary lesions.

BACKGROUND: The outcome of drug-eluting stent (DES) implantation in long coronary lesions remains unclear.

METHODS: The study involved 527 patients with de novo long coronary lesions (> or = 24 mm), which were treated with long (> or = 28 mm) SESs (223 lesions), PESs (194 lesions), or BMSs (201 lesions).

RESULTS: Lesions in the SES (36.0 +/- 14.9 mm, P < 0.001) and PES (36.3 +/- 14.5 mm, P < 0.001) groups were longer than those in the BMS group (32.0 +/- 12.3 mm), meaning the two DES groups had longer stented segments than did the BMS group. Six-month angiographic follow-up showed the SES (9.3%, P < 0.001) and PES (21.3%, P < 0.001) groups had lower in-segment restenosis rates than that of the BMS group (42.5%). The rate of major adverse cardiac events (MACE) including death, myocardial infarction, and target lesion revascularization at 9 months was higher in the BMS group (26.6%) than that in the SES (13.0%, P < 0.001) and PES (15.7%, P < 0.001) groups. Posthoc analysis of the two DES groups showed that the in-segment restenosis rate was lower for the SES than that for the PES group (P = 0.002), while the MACE rate was similar.

CONCLUSIONS: The use of DESs for long coronary lesions appears to be safe and more effective than the use of BMSs in terms of restenosis and adverse clinical events. SES use was associated with lower late luminal loss and a lower angiographic restenosis rate compared with PES use.
dc.subject.MESHAnalysis of Variance-
dc.subject.MESHCardiovascular Agents/administration & dosage*-
dc.subject.MESHChi-Square Distribution-
dc.subject.MESHCoronary Angiography-
dc.subject.MESHCoronary Artery Disease/therapy*-
dc.subject.MESHCoronary Restenosis/prevention & control-
dc.subject.MESHDrug Delivery Systems-
dc.subject.MESHLogistic Models-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPaclitaxel/administration & dosage*-
dc.subject.MESHProspective Studies-
dc.subject.MESHSirolimus/administration & dosage*-
dc.titleComparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions.-
dc.contributor.affiliatedAuthor탁, 승제-
dc.type.localJournal Papers-
dc.citation.titleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions-
dc.identifier.bibliographicCitationCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 67(2):181-187, 2006-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Cardiology
Files in This Item:
There are no files associated with this item.


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.